Propanc Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Propanc Biopharma Inc (PPCH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Propanc Biopharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Propanc Biopharma Inc | - | - | - | No |
| Competitors combined (37) | ||||
| High-Confidence Competitors (11) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PPCH Stock Performance relative to its Competitors
PPCH Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 4 | 89bio Inc | 282.9% | Outperformed |
| 5 | Oramed Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Propanc Biopharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Propanc Biopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Propanc Biopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Propanc Biopharma Inc |
- | - |
 Madrigal Pharmaceuticals Inc |
13,125.59 | 1,427.94 |
 Nuvalent Inc |
9,751.98 | 4.23 |
 Rhythm Pharmaceuticals Inc |
7,847.77 | 280.75 |
 Terns Pharmaceuticals Inc |
4,933.17 | - |
 Kazia Therapeutics Limited |
4,202.71 | 0.03 |
| SUBTOTAL | 63,646.02 | 4,516.38 |
Sign in to see all competitors of Propanc Biopharma Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Propanc Biopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Propanc Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from Propanc Biopharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| MacroGenics, Inc. | Company report | 85% |
| Vivesto AB (formerly, Oasmia Pharmaceutical AB) | Company report | 85% |
| AbbVie, Inc. | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Novartis AG | Company report | 85% |
| Pharma Mar S.A. | Company report | 85% |
| Boehringer Ingelheim International GmbH | Company report | 85% |
| Gradalis, Inc. | Company report | 85% |
| Oncotelic Therapeutics, Inc. (formerly, Mateon Therapeutics, Inc.) | Company report | 85% |
| AstraZeneca PLC (Acerta Pharma) | Company report | 85% |
| Kazia Therapeutics Limited (formerly, Novogen Limited) | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Chugai Pharmaceutical Co., Ltd. | Company report | 85% |
| GSK plc (formerly, GlaxoSmithKline plc (Tesaro)) | Company report | 85% |
| Merck & Co., Inc. | Company report | 85% |
| Pfizer, Inc. | Company report | 85% |
| Oasmia Pharmaceuticals, Inc. | Company report | 85% |
| Clovis Oncology | Company report | 85% |
| Mateon Therapeutics, Inc. | Company report | 85% |
| Five Prime Therapeutics, Inc. | Company report | 85% |
| Novogen Limited | Company report | 85% |
| Boehringer Ingelheim GmbH | Company report | 85% |
| GlaxoSmithKline plc (Tesaro) | Company report | 85% |
Company report basis, confidence, active dates and source counts for Propanc Biopharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Propanc Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Propanc Biopharma Inc .
Propanc Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Propanc Biopharma Inc | - | - | -9,431,355 |
| Madrigal Pharmaceuticals Inc | 13,126 | 1,560,590 | -169,905 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Rhythm Pharmaceuticals Inc | 7,848 | 678,135 | -476,599 |
| Terns Pharmaceuticals Inc | 4,933 | - | -1,630,627 |
| Kazia Therapeutics Limited | 4,203 | 579 | -285,369 |
| PEERS TOTAL | 63,646 | 789,164 | -297,741 |
Sign in to see all peers for Propanc Biopharma Inc .
Propanc Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Iovance Biotherapeutics inc | US 98.66 % |
| Hutchmed china Limited | CN 74.28 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Propanc Biopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 492 companies in Propanc Biopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Propanc Biopharma Inc ranks #0 of 492 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 975, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 23.62 % |
| 2 | Johnson and Johnson | 688,377 | 12.89 % |
| 3 | Abbvie Inc | 519,434 | 9.73 % |
| 4 | Merck and Co Inc | 367,314 | 6.88 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Propanc Biopharma Inc | 31 | 0.00 % |
Market cap and industry share for the rest of Propanc Biopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2017-05-31.
Propanc Biopharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - | - | - | -215.22 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Propanc Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 975 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Propanc Biopharma Inc's dedicated Suppliers and Customers pages, not here.
Propanc Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 175.2 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-13.6% annualized).
Methodology: see Methodology: SWOT Analysis.
Propanc Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Propanc Biopharma Inc | 0.12 | 2.12 | 0.02 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Rhythm Pharmaceuticals Inc | 1.01 | 3.60 | 0.94 |
| Terns Pharmaceuticals Inc | 17.26 | 35.60 | - |
| Kazia Therapeutics Limited | 0.31 | 0.35 | - |
Sign in to see all peers for Propanc Biopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Propanc Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Propanc Biopharma Inc | Q2 2026 | - | - |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +79.6 % | - |
| Terns Pharmaceuticals Inc | Q4 2025 | - | - |
| Kazia Therapeutics Limited | Q2 2025 | -98.2 % | - |
| PEERS TOTAL | +63.2 % | - |
Sign in to see all peers for Propanc Biopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Propanc Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Propanc Biopharma Inc | Q2 2026 | - | - |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +121.2 % | -98.8 % |
| Terns Pharmaceuticals Inc | Q4 2025 | - | - |
| Kazia Therapeutics Limited | Q2 2025 | - | - |
Sign in to see all peers for Propanc Biopharma Inc .
Propanc Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Propanc Biopharma Inc | - | - | - |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Rhythm Pharmaceuticals Inc | - | - | - |
| Terns Pharmaceuticals Inc | - | - | - |
| Kazia Therapeutics Limited | - | - | - |
Sign in to see all peers for Propanc Biopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Propanc Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Propanc Biopharma Inc | - | - |
| Madrigal Pharmaceuticals Inc | - | 9.19 |
| Nuvalent Inc | - | 2,303.80 |
| Rhythm Pharmaceuticals Inc | - | 27.95 |
| Terns Pharmaceuticals Inc | - | - |
| Kazia Therapeutics Limited | - | 154,450.18 |
| PEERS AVERAGE | - | 14.09 |
Sign in to see all peers for Propanc Biopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.